NAV
$29.46
AUM
$41.0M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.87
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +9.06% | +20.11% | +19.14% | +24.89% | +5.83% | -0.56% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | UCB.BR | UCB SA | 4.73% |
| 2 | LFST | LifeStance Health Group Inc Ordinary Shares | 4.27% |
| 3 | DHR | Danaher Corp | 3.42% |
| 4 | TXG | 10x Genomics Inc Ordinary Shares - Class A | 3.11% |
| 5 | ISRG | Intuitive Surgical Inc | 2.92% |
| 6 | COGT | Cogent Biosciences Inc | 2.85% |
| 7 | ALNY | Alnylam Pharmaceuticals Inc | 2.79% |
| 8 | ARGX | argenx SE ADR | 2.78% |
| 9 | LEGN | Legend Biotech Corp ADR | 2.29% |
The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.
Inception Date: 2020-04-16